6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
31m ago	Sunrun Prices $584 million Securitization of Residential Solar and Storage Assets
31m ago	Madison Air Schedules First Quarter 2026 Earnings Conference Call and Webcast
55m ago	Ultra Clean Announces Retirement of the Chief Financial Officer Sheri Savage
55m ago	GridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filing
55m ago	Rush Enterprises, Inc. Reports First Quarter 2026 Results, Announces $0.19 Per Share Dividend

About

Roivant Sciences Ltd (NASDAQ:ROIV) — investor relations, events, news, and company updates on 6ix.

Latest News

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

Financials

Revenue

$13.31 M

Market Cap

$20.28 B

EPS

-1.17

Community Chat

Ask AI